TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $145
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $140 to $145.
TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $140 to $145.